Scientists have figured out all the steps to make morphine and similar painkillers without using opium poppies, potentially opening the door for home-brewed drugs. Some experts are calling for regulations to prevent tinkerers from making morphine, which can be converted into heroin.
Beach dwellers in Alabama and North Carolina have stumbled upon bulky packages worth thousands...
Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they...
Colombian President Santos last week decided to halt fumigation in the wake of a report by a...
Thirteen percent of drugs marketed in the United States today post pharmacogenomic information on the label, but developers continue to encounter compliance challenges.
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, today announced its financial results for the first quarter.
ProPharma Group, a compliance services company, today announced its acquisition of PROSAR, a provider of pharmacovigilance and medical information services.
Sigma-Aldrich Corporation has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing.
State senators, for a second time, have sent legislation legalizing medical marijuana to the House of Representatives, where the GOP majority has held hearings but given no certain signs of support.
ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals.
Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.
Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.
Sigma-Aldrich Corporation's new facility will support commercial-scale gene therapy production, testing and filling.
Juno Therapeutics, a biopharmaceutical company focused on cancer treatment, announced today that it has acquired Stage Cell Therapeutics GmbH.
Inovio Pharmaceuticals announced that the company has initiated a phase I trial to evaluate the safety, tolerability and immune responses of their DNA immunotherapy for Ebola.
Mexico's public health system has suspended infant vaccines and mounted an investigation after vaccinations for tuberculosis, rotovirus and Hepatitis B resulted in devestation for an impoverished southern community.
Saturday marked 42 days since Liberia's last Ebola case — the benchmark used to declare the outbreak over. The epidemic claimed more than 4,700 lives in the country.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer provided an update of its three clinical development programs.
The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator for the prevention of oral mucositis.
Bellicum Pharmaceuticals, Inc. today announced that it has entered into a lease agreement to enable in-house cell therapy manufacturing to supply clinical trials.
For the first time, Ebola has been discovered inside the eyes of a patient months after the virus was gone from his blood.
A huge nationwide spike in hospitalizations last month was caused by a class of drugs often called synthetic marijuana, possibly illustrating the potency and dangers of the chemicals used to make them.
The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.
Prick a finger and have the blood checked for parasites — by smartphone?
Dr. Cooper brings extensive experience in pioneering the development of adoptive cellular therapies in the field of oncology and translating immunology into clinical practice.
MorphoSys AG announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Eli Lilly and Company today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts.
Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.
- Page 1